HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Carbon ion irradiation plus CTLA4 blockade elicits therapeutic immune responses in a murine tumor model.

Abstract
Radiotherapy can act as an in situ vaccine, activating preventive tumor-specific immune responses in patients. Although carbon ion radiotherapy has superior biophysical properties over conventional photon irradiation, the immunological effects induced by this radiation type are poorly understood. Multiple strategies combining radiotherapy with immune checkpoint inhibition (radioimmunotherapy) to enhance antitumor immunity have been described; however, immune cell composition in tumors following radioimmunotherapy with carbon ions remains poorly explored. We developed a bilateral tumor model based on time-shifted subcutaneous injection of murine Her2+ EO771 tumor cells into immune-competent mice followed by selective irradiation of the primary tumor. αCTLA4-, but not αPD-L1-based radioimmunotherapy, induced complete tumor rejection and mediated the eradication of even non-irradiated, distant tumors. Cured mice were protected against the EO771 rechallenge, indicating long-lasting, tumor-specific immunological memory. Single-cell RNA sequencing and flow cytometric analyses of irradiated tumors revealed activation of NK cells and distinct tumor-associated macrophage clusters with upregulated expression of TNF and IL1 responsive genes. Distant tumors in the irradiated mice showed higher frequencies of naïve T cells activated upon the combination with CTLA4 blockade. Thus, radioimmunotherapy with carbon ions plus CTLA4 inhibition reshapes the tumor-infiltrating immune cell composition and can induce complete rejection even of non-irradiated tumors. Our data suggest combining radiotherapy approaches with CTLA4 blockade to achieve durable antitumor immunity. Evaluation of future radioimmunotherapy approaches should not be restricted to immunological impact at the irradiation site but should also consider systemic immunological effects on non-irradiated tumors.
AuthorsLaura Hartmann, Wolfram Osen, Oliver L Eichmüller, Theresa Kordaß, Jennifer Furkel, Elke Dickes, Carissa Reid, Jürgen Debus, Stephan Brons, Amir Abdollahi, Mahmoud Moustafa, Stefan Rieken, Stefan B Eichmüller
JournalCancer letters (Cancer Lett) Vol. 550 Pg. 215928 (12 01 2022) ISSN: 1872-7980 [Electronic] Ireland
PMID36183858 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2022. Published by Elsevier B.V.
Chemical References
  • CTLA-4 Antigen
  • Immune Checkpoint Inhibitors
  • Carbon
Topics
  • Animals
  • CTLA-4 Antigen
  • Carbon
  • Cell Line, Tumor
  • Heavy Ion Radiotherapy
  • Immune Checkpoint Inhibitors
  • Immunologic Memory
  • Mice

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: